semaglutide kidney side effects FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Semaglutide in chronic kidney disease

In the ETDRS, diabetic macular edema (DME) was characterized as "clinically significant" if any of the following were noted (Figure 6): retinal thickening within 500 microns of the fovea, hard exudates within 500 microns of the fovea if associated with adjacent retinal thickening, or an area of retinal thickening 1 disc diameter or larger if any part of it is located within 1 disc diameter of the fovea (86)

[DOI] [PMC free article] [PubMed] [Google Scholar] 11.Kabahizi A., Wallace B., Lieu L., Chau D., Dong Y., Hwang E.S., Williams K.W

Abstract Background Off-label use of semaglutide for non-diabetic weight loss (which regulators have linked to social media promotion) created worldwide supply shortages

What should I do if QR verification fails

We don't prohibit it

From a pharmacist perspective, this does mean clinicians should be mindful of patients presenting with new sensory symptoms after starting semaglutide